Guidelines for treatment of drug-susceptible tuberculosis and patient care
Update 2017
October 2018
HIV testing services
This document aims to provide concrete, pragmatic guidance for how TB modelling and related technical assistance is undertaken to support country decision-making. The target audience for this document are the participants and stakeholders in country-level TB modelling efforts, including the individu...als who build and apply models; policy-makers, technical experts and other members of the TB community; international funding and technical partners; and individuals and organizations engaged in supporting TB policy-making.
more
This report looks at how the current implications of COVID-19 is exacerbating key challenges for people who menstruate around the world and provides recommendations on how to include menstrual hygiene management (MHM) within a COVID-19 response.
This guidance provides considerations and a series of options that can be used to inform country strategies in managing any shortages of personal protective equipment.Re-use and reprocessing of single-use PPE must be a last resort temporary measure to be adopted until stocks are replenished. The WH...O and other agencies are currently conducting research about this and further guidance will likely become available soon.
more
Twenty-Fourth Annual Trachoma Control Program Review, Summary Proceedings
Of the 50 antibiotics in the pipeline, 32 target WHO priority pathogens but the majority have only limited benefits when compared to existing antibiotics. Two of these are active against the multi-drug resistant Gram-negative bacteria, which are spreading rapidly and require urgent solutions.
Gr...am-negative bacteria, such as Klebsiella pneumoniae and Escherichia coli, can cause severe and often deadly infections that pose a particular threat for people with weak or not yet fully developed immune systems, including newborns, ageing populations, people undergoing surgery and cancer treatment.
The report highlights a worrying gap in activity against the highly resistant NDM-1 (New Delhi metallo-beta-lactamase 1), with only three antibiotics in the pipeline. NDM-1 makes bacteria resistant to a broad range of antibiotics, including those from the carbapenem family, which today are the last line of defence against antibiotic-resistant bacterial infections.
more
Human Resources for Health Observer Series No. 16